Disease · MONDO_0005803

hyperinsulinemic hypoglycemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hyperinsulinemic hypoglycemia. Diseases, record MONDO_0005803. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005803

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hyperinsulinemic hypoglycemia; Open Targets
Open Targets ID: MONDO_0005803; Open Targets
Other names: Islet cell hyperplasia, Nesidioblastosis, hyperinsulinemia hypoglycemia, hyperinsulinemic hypoglycemia (disease), persistent hyperinsulinemia hypoglycemia of infancy; Open Targets
Disease Ontology: DOID:13317; Disease Ontology
Orphanet: ORPHA:443095; Orphanet
Highest stage of its drugs: Approval, for 1 of its 9 drugs, from PMDA; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DIAZOXIDE	CHEMBL181	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
AVEXITIDE	CHEMBL4297949	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GLUCAGON	CHEMBL5314341	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PASIREOTIDE	CHEMBL3349607	Protein	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ATROPINE	CHEMBL517712	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXTROSE	CHEMBL1222250	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets
GLUCAGON-LIKE PEPTIDE 1	CHEMBL4594475	Protein	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SSTR1	Somatostatin receptor	2	Somatostatin receptor 1 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	2	Somatostatin receptor 2 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	2	Somatostatin receptor 3 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR5	Somatostatin receptor	2	Somatostatin receptor 5 agonist; Somatostatin receptor agonist	Phase 2	https://conductscience.org/library/genes/6755	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	1	Muscarinic acetylcholine receptor M1 antagonist	Early phase 1	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	1	Muscarinic acetylcholine receptor M2 antagonist	Early phase 1	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 antagonist	Early phase 1	https://conductscience.org/library/genes/1131	Drugs and targets
GCGR	Glucagon receptor	1	Glucagon receptor agonist	Phase 2	https://conductscience.org/library/genes/2642	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
KCNJ11	ATP-sensitive inward rectifier potassium channel 11	1	Potassium channel, inwardly rectifying, subfamily J, member 11 opener	Approval	https://conductscience.org/library/genes/3767	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04652479	Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia	Phase 2	25	2023-06-09	Acquired Hyperinsulinemic Hypoglycemia	AVEXITIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00992901	Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery	Early phase 1	160		Post Bariatricsurgery, Hypoglycemia	ATROPINE, AVEXITIDE, GLUCAGON-LIKE PEPTIDE 1	Its record names the disease	ClinicalTrials.gov
NCT03770637	Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery	Phase 2	14		Hyperinsulinemic Hypoglycemia	GLUCAGON	Its record names the disease	ClinicalTrials.gov
NCT00987168	Sandostatine® LP and Hyperinsulinism	Phase 2	10		Congenital Hyperinsulinism	OCTREOTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03103009	Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia	Phase 1	1		Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia	PASIREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT04984798	Vitamin E Efficacy in HI/HA	Phase 2	0		Hyperinsulinism-Hyperammonemia Syndrome	VITAMIN E	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
42744082	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005803

GET https://conductscience.org/api/diseases/v1/MONDO_0005803/drugs

API reference For AI assistants